T细胞非霍奇金淋巴瘤多种治疗方案的疗效比较  

Comparison of efficacy of multiple treatment regimen for T cell non-Hodgkin lymphoma

作　　者：余永卫[1] 王鲁霞[1] 陈庆生[1] 李雪丽[1] 宁晓梅[1] 黄玮[1] 黄丹池[1] 张晓霞[1] 骆碧香[1] 

机构地区：[1]广东省佛山市第二人民医院血液科,528000

出　　处：《白血病．淋巴瘤》2010年第2期94-96,共3页Journal of Leukemia & Lymphoma

摘　　要：目的探讨CHOP、CTOP和CTOPL方案以及干扰素治疗T细胞非霍奇金淋巴瘤（NHL）的治疗效果。方法用三种化疗方案治疗T细胞NHL40例，CHOP方案治疗15例，CTOP方案治疗18例，CTOPL方案治疗7例，用干扰素治疗皮肤T细胞NHL6例。结果CHOP方案组化疗后CR10例（66．7％），PR2例（13．3％），PD3例（20．0％）。CTOP方案组CR13例（72．2％），PR3例（16．7％），PD1例（5．6％），早期死亡1例（5．6％）。CTOPL方案组CR5例（71．4％），PR2例（28．6％）。三组之间CR,PR和PD比较，差异均无统计学意义（P〉0．05）。干扰素治疗组病情均完全缓解。CHOP方案化疗长期生存2例，CTOP方案4例，CTOPL方案3例，干扰素治疗长期生存4例。结论CTOP和CTOPL方案是目前临床上治疗T细胞NHL较好的方案，但如何克服T细胞NHL的耐药性仍需在临床上进一步探讨。Objective To evaluate the efficacy of muhiple chemotherapy regimens for T cell non- Hodgkin lymphoma. Methods 40 cases of T cell non-Hodgkin lymphoma were treated with three different regimens. 15 cases were treated with CHOP regimen; 18 cases with CTOP regimen; 7 cases with CTOPL regimen; and 6 cases in skin T cell non-Hodgkin lymphoma were treated with Interferon. Results In the CHOP group 10 cases （66.7 %） achieved complete remission （CR）, 2 cases （13.3 %） PR, and 3 cases （20.0 %） PD. In the CTOP group 13 cases （72.2 %） achieved CR, 3 cases （16.7 %） PR, one case （5.6 %） PD, and one case （5.6 %） died at the early stage. In the CTOPL group 5 cases （71.4 %） achieved CR, and 2 cases （28.6 %） PR. Three group were compared with each other, respectively, and there was no statistical difference （P 〉0.05）. In the Interferon group all patients achieved CR. In the CHOP group 2 patients of skin lymphoma achieved the long term survival, but in the CTOP and CTOPL groups of 7 patients survived long term. Conclusion CTOP and CTOPL regimen may be more effective for treatment of T cell non-Hodgkin lymphoma with better long term survival rate, but further investigation to overcome the drug resistance in T cell non- Hodgkin lymphoma needs to be carried out.

关 键 词：T淋巴细胞 淋巴瘤 非霍奇金 药物疗法 联合 

分 类 号：R733.1[医药卫生—肿瘤]